Skip to content

Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children

Double-blind, Parallel, Randomized, (Placebo-controlled) Explorative Study on the Effect of a Mixture of Prebiotic Oligosaccharides on the Composition of Intestinal Microbiota and Selected Health Outcomes in Children 3 to 6 Years of Age

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03241355
Enrollment
258
Registered
2017-08-07
Start date
2013-09-16
Completion date
2014-04-28
Last updated
2018-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Only, Diet Modification, Infectious Disease

Brief summary

The study aims to explore whether prophylactic dietary supplementation with prebiotic inulin-type fructans is able to influence the intestinal microbiota and the frequency of infectious disease episodes in kindergarten children during a winter period.

Interventions

DIETARY_SUPPLEMENTprebiotic inulin-type fructan
DIETARY_SUPPLEMENTPlacebo maltodextrin

Sponsors

Beneo-Institute
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 6 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is healthy at the time of pre-examination * Subject is aged 3-6 years at the time of pre-examination * Subject attends a kindergarten at the time of pre-examination

Exclusion criteria

* congenital disease or malformation influencing the gastrointestinal System * children with congenital or acquired immunodeficiency * children with food intolerance, food allergy or metabolic disorder requiring special diet * children who regularly (more than 3 times per week) consumed products or food supplements containing prebiotics or probiotics * children who consumed antibiotics or laxatives within 14 days * children who had any infectious disease within 14 days at the time of pre-examination

Design outcomes

Primary

MeasureTime frame
Frequency of infectious disease episodes24 weeks period

Secondary

MeasureTime frameDescription
microbiota composition24 weeks periodfecal microbiota composition (qPCR, illumina)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026